HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Warning Letter Barrage Continues With Five More To Close July

This article was originally published in The Rose Sheet

Executive Summary

At least nine skin-care marketers received FDA warning letters in July for unapproved drug claims. In the month’s final two weeks, recipients included companies behind the Freeze 24-7 Instant Targeted Wrinkle Treatment and a Resurgent Stem Cell Firming Activator, among others.

You may also be interested in...

Probiotic Skin Care Could Be Gutsy Move In US Regulatory Environment

Findings that oral probiotics may not only benefit digestive health but also potentially alleviate inflammatory skin disorders are contentious but have driven uptake of probiotic ingredients by cosmetic players. Market opportunity is growing, but probiotic skin-care claims could be liabilities in the US where FDA increasingly has been citing statements about immunotherapeutic and anti-inflammatory effects in warning letters.

FDA Warns Saintly Skin-Care Brand For Claims Transgressions

Harrington House’s Abbey St. Clare brand must atone for online skin-care claims that violate federal law per an FDA warning letter. The agency also recently posted a warning issued to Aloe Farms in July, the busiest month for cosmetic claims enforcement in FDA’s history.

Michael Todd, ‘Where Science Meets Nature,’ Meets FDA Warning Letter

Port St. Lucie, Fla.-based firm’s Intensive Eye Treatment and Knu Anti-Aging Face Lift Serum are unapproved drugs based on claims featured online, FDA says. The July 18 warning letter, posted to the agency’s website Aug. 16, was one of at least 10 that issued to skin-care companies in July.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts